Rapastinel alleviates the neurotoxic effect induced by NMDA receptor blockade in the early postnatal mouse brain
Rapastinel is a novel psychoactive substance that acts as an N-methyl-D-aspartate-receptor (NMDAR) agonist and triggers antidepressant- and antipsychotic-like effects in animal models. However, it is unknown if rapastinel possesses a better side-effect profile than fast-acting glutamatergic antidepr...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 2021
|
| In: |
European archives of psychiatry and clinical neuroscience
Year: 2021, Volume: 271, Issue: 8, Pages: 1587-1591 |
| ISSN: | 1433-8491 |
| DOI: | 10.1007/s00406-020-01180-5 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00406-020-01180-5 Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s00406-020-01180-5 |
| Author Notes: | Andrei-Nicolae Vasilescu, Anne Mallien, Natascha Pfeiffer, Undine E. Lang, Peter Gass, Dragos Inta |
| Summary: | Rapastinel is a novel psychoactive substance that acts as an N-methyl-D-aspartate-receptor (NMDAR) agonist and triggers antidepressant- and antipsychotic-like effects in animal models. However, it is unknown if rapastinel possesses a better side-effect profile than fast-acting glutamatergic antidepressants, like ketamine, which trigger neurotoxicity in the perinatal rodent cortex and protracted schizophrenia-like alterations. Here we found a remarkable neuroprotective effect of rapastinel against apoptosis induced by the NMDAR antagonist MK-801 in comparison to that elicited by clozapine and the mGlu2/3 agonist LY354740. These results suggest the potential therapeutic/prophylactic effect of rapastinel in ameliorating deleterious effects induced by NMDAR blockade during neurodevelopment. |
|---|---|
| Item Description: | Online publiziert: 13. August 2020 Gesehen am 23.04.2026 |
| Physical Description: | Online Resource |
| ISSN: | 1433-8491 |
| DOI: | 10.1007/s00406-020-01180-5 |